<DOC>
	<DOC>NCT02672462</DOC>
	<brief_summary>A single center, self-controlled pilot study on safety and efficacy of renal denervation in treatment of hypertension.</brief_summary>
	<brief_title>Renal Denervation for the Treatment of Hypertension: A Pilot Safety and Efficacy Study</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<criteria>Ages of 18 to 75, male or female; Main renal artery, with or without accessary renal arteries, with length 20mm; Patients who have not taken any antihypertensive drugs or have been off drugs for at least 2 weeks, with mean SBP ≥150mmHg and 180mmHg based on at least 3 office blood pressure measurements, or ASBP≥135mmHg and ≤170mmHg based on 24 hr blood pressure monitoring; Agrees to take part in the trial and signs the written, informed consent. Renal artery abnormalities that are inappropriate for the procedure; Pregnant or plan to become pregnant; History of orthostatic hypotension; Type I diabetes; Estimated GFR&lt;40mL/min/1.73m2; Only one kidney or prior kidney transplantation; Bleeding tendency or other coagulation related diseases; Acute or severe systemic infection; Prior renal artery interventional procedures or prior RDN treatment; History of stroke or TIA; Malignant tumor or endstage illnesses; Secondary hypertension; Acute coronary events within 2 weeks; Other conditions that deem unsuitable for the procedure, in the opinions of investigators.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>